Goodman Tony 4

What Happened

• Tony Goodman, Chief Operating Officer of Adial Pharmaceuticals (ADIL), was granted 26,510 restricted shares on April 7, 2026. The shares were issued at an acquisition price of $0.00 (transaction code A — award/grant).

Key Details

• Transaction date: 2026-04-07; Form 4 filed 2026-04-09 (timely within the SEC’s 2-business-day window).
• Shares granted: 26,510 restricted common shares; acquisition price reported as $0.00.
• Shares owned after the transaction: not specified in this filing.
• Vesting/footnote: grant vests in full on the earlier of (i) the one‑year anniversary of the grant date (around 2027-04-07) or (ii) a Change of Control per the company’s 2017 Equity Incentive Plan, subject to Goodman’s continued service through the vesting date.

Context

• This is a compensation award (restricted stock) rather than an open‑market purchase or sale. Such grants are routine for employee compensation and are subject to vesting conditions; they do not by themselves indicate an insider buying or selling on market sentiment.